Acebrophylline 200MG with Montelukast 10MG and Desloratadine 5MG Tablets – A combination medication which is a multi compnent solid oral dosage form with three potent Ingredients at specified strengths- 200mg, 10mg and 5mg. Incorporating such a combination demands a unified control of materials which have different physical and analytical traits to be distributed appropriately and find the desired powder flow properties and tablet compression properties. This can be added as a part of multi potential PCD Pharma Franchise product list for pharma companies.
A three-active formulation involves a more complex development process than a single component tablet. The amount of each ingredient, particle properties, mix sequence, compression properties and analytical method will all need to be thought through in order to produce a consistent finished tablet.
Stage 1 - Developing Knowledge of Acebrophylline, Montelukast and Desloratadine Individual Properties All of the actives may possess varying particle sizes, densities, flow properties and physical sensitivities to the environment. These factors are taken into account when developing the overall formulation.
Excipients are chosen to facilitate the manufacturing process of the combined formulation. In some cases, they may form part of the formulation, providing benefits such as binding, enhanced flow, lubrication, compression and tablet integrity. Compatibility testing between the three active ingredients and the excipient system is an important part of the selection process.
All manufacturing processes should be closely monitored during material dispensing as the formulation consists of three individual active ingredients. All ingredients should be weighed to the approved formulation specification and recorded before going into the processing stage. Material identification and staging are controlled to aid traceability and minimise formulation errors.
The most important technical aspect of a three-active tablet is the uniform distribution. Particles with different size and density will tend to segregate if powders are not handled in a suitable manner.
Particle-size conditioning, sieving, geometric dilution, pre-blending, or other appropriate procedures can also be employed in the manufacturing process, depending on the formulation design. During development, the order of addition of material can be determined to ensure the low-range materials are thoroughly and evenly dispersed throughout the larger formulation.
Mixing parameters are established in formulation and process-development studies. The factors involved are powder blending time, methods used for equipment loading and transfer, etc., ensuring a uniform powder mixture.
You can also determine the representative blend samples at specified points. The analytical tests ensure proper distribution of acebrophylline, montelukast and desloratadine in the blend before compression. Gentle transfer of powder is significant because vibration or sudden acceleration might have an effect on the uniformity of the blend.
Once the desired mixture profile is obtained, the formulation is transferred to the tablet compression stage. During compression, the entire three-component mixture must be taken into account and not just one isolated ingredient.
The speed of the machine, compression force, tooling and powder-feed rates are monitored to produce tablets with uniform weight, pressure and mechanical properties. The formulation may need to be adjusted by changing the compression conditions to improve the strength of the tablets.
In-process tablet checks may involve weighing, thickness testing, hardness, friability or visual examination of tablets. Common defects associated with the compression process, such as sticking, capping, lamination and edge damage can also be inspected.
Once tablets are formed, dedusting, inspection and compression can be performed prior to sending the tablets across to the packaging area. This is also a stage at which continued handling can be used to preserve the physical quality of the finished dosage form.
Can you explain any challenges you faced in the quality testing of a tablet with 3 actives? The analytical approach to quality testing of a tablet with 3 actives was to ensure the detection and measurement of acebrophylline, montelukast and desloratadine separately in accordance with the approved specification.
Appropriate analytical methods should have sufficient specificity to separate the individual substances in the combined product(s). Finished-product testing may involve identification, assay, disintegration, dissolution, uniformity and other test(s) applicable to the quality of the preparation.
Sampling methods should be designed to represent the lot of material. In addition to finished-product testing, in-process and blend-stage testing can be used to monitor manufacturing consistency.
Batch manufacturing records, lab test results, raw-material records and packaging records all contribute to product traceability. Full documentation helps to support a process where all manufacturing stages are verifiable against their specifications.
Stability assessment includes the three active ingredients in the finished formulation. Storage studies may measure relevant physical and chemical properties at specified intervals under specified conditions.
The chosen packaging provides sufficient protection of the tablets for the prescribed storage period of the product. For the final specification blister packs or other pharmaceutical packagings systems may be used. Moisture barriers, seal integrity, compatibility of materials and labelling are some of the factors to be addressed.
The packaging system must also allow enough room for the identification of product, batch details, manufacturing information and other approved labeling. Uniform packaging enables all products to be presented in a similar way and helps with proper stock control.
Expand your product portfolio by including Acebrophylline 200MG with Montelukast 10MG and Desloratadine 5MG Tablets The Acebrophylline 200MG with Montelukast 10MG and Desloratadine 5MG Tablets can be part of a well managed PCD Pharma Franchise Product List by pharmaceutical companies who want to offer a comprehensive list. Controlled composition development, various component analytical testing, stable packing and documented manufacturing process.
The overall evolution of this blend incorporates the synchronization of raw-material qualification, blend engineering, compression technology, analytical and stability screening as well as packaging. The optimal process will enable the batch-to-batch consistency of the quality profile of the finished tablets.
Acebrophylline 200mg Montelukast 10mg Desloratadine 5mg Tablets covering formulation, quality testing, stability and PCD Pharma details.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech